Check out Total Prescribing Facts OPDIVO® (nivolumab) is indicated to the treatment of Grownup patients with classical Hodgkin lymphoma (cHL) which includes relapsed or progressed soon after autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or immediately af